Human Umbilical Cord Mesenchymal Stem Cell in Cerebral Hemorrhage Sequela

Shenzhen Hornetcorn Biotechnology

Status and phase

Unknown

Phase 1

Conditions

Cerebral Hemorrhage

Treatments

Biological: Human umbilical cord mesenchymal stem cells

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT02283879

HYK-Cerebral hemorrhage

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell(hUC-MSC) for cerebral hemorrhage sequela.

Full description

Human umbilical cord mesenchymal stem cells exhibit the potential to differentiate into neural cells, which have been confirmed in in vivo and in vitro experiments. There have been few clinical reports describing umbilical cord mesenchymal stem cells for treatment of cerebral hemorrhage.

To investigate the effects of hUC-MSC treatment for cerebral hemorrhage sequela, 20 patients with cerebral hemorrhage will be enrolled and receive 4 times of hUC-MSC transplantation.

Enrollment

20 estimated patients

Sex

All

Ages

40 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Aged 40-70 intracerebral hemorrhage patient
With stroke history of more than 3 months, less than 60 months
National Institutes of Health stroke scale(NIHSS) score of 7 or more points
Patient is stable (normal respiration, afebrile, BP less than mean arterial pressure of 125 mm of Hg, fasting blood sugar <7 mg, and normal urea/electrolytes for at least 48 hours.)

Exclusion criteria

History of neurological disease, head injury or psychiatric disorder;
Pregnant women;
Impaired liver function, abnormal blood coagulation, AIDS, HIV, combine other tumor or special condition;
Progressive apoplexy;
With malignant tumors.